FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894897498> ?p ?o ?g. }

• W2894897498 endingPage "1609" @default.
• W2894897498 startingPage "1601" @default.
• W2894897498 abstract "Platelets participate in the development of liver fibrosis in animal models, but little is known about the benefit of antiplatelet agents in preventing liver fibrosis in humans. We therefore explored the relationship between the use of antiplatelet agents and liver fibrosis in a prospective cohort study of patients at high risk of liver fibrosis and cardiovascular events. Consecutive patients undergoing elective coronary angiography at the University Hospital Frankfurt were prospectively included in the present study. Associations between use of antiplatelet agents (acetyl salicylic acid, P2Y12 receptor antagonists) and liver fibrosis were assessed in regression models, and the relationship between platelet-derived growth factor beta (PDGF-β) serum concentration, platelets, liver fibrosis, and use of antiplatelet agents was characterized. Out of 505 included patients, 337 (67%) received antiplatelet agents and 134 (27%) had liver fibrosis defined as a FibroScan transient elastography (TE) value ≥7.9 kPa. Use of antiplatelet agents was inversely associated with the presence of liver fibrosis in univariate and multivariate analyses (multivariate odds ratio [OR], 0.67; 95% confidence interval [CI], 0.51-0.89; P = 0.006). Use of antiplatelet agents was also inversely associated with FibroTest values (beta, –0.38; SD beta, 0.15; P = 0.02). Furthermore, there was a significant correlation between platelet counts and PDGF-β serum concentration (rho, 0.33; P < 0.0001), but PDGF-β serum levels were not affected by antiplatelet agents. Conclusion: There is a protective association between the use of antiplatelet agents and occurrence of liver fibrosis. A randomized controlled trial is needed to explore causality and the potential of antiplatelet agents as antifibrotic therapy in patients at risk for liver fibrosis progression." @default.
• W2894897498 created "2018-10-12" @default.
• W2894897498 creator A5005730211 @default.
• W2894897498 creator A5017596026 @default.
• W2894897498 creator A5027038914 @default.
• W2894897498 creator A5035012194 @default.
• W2894897498 creator A5045504446 @default.
• W2894897498 creator A5056496986 @default.
• W2894897498 creator A5061607493 @default.
• W2894897498 creator A5075606570 @default.
• W2894897498 creator A5078994052 @default.
• W2894897498 creator A5090710640 @default.
• W2894897498 date "2018-10-05" @default.
• W2894897498 modified "2023-10-14" @default.
• W2894897498 title "Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease" @default.
• W2894897498 cites W1856151485 @default.
• W2894897498 cites W1971197010 @default.
• W2894897498 cites W1983586642 @default.
• W2894897498 cites W1990341278 @default.
• W2894897498 cites W1993518161 @default.
• W2894897498 cites W2002719027 @default.
• W2894897498 cites W2007486557 @default.
• W2894897498 cites W2008342366 @default.
• W2894897498 cites W2019744283 @default.
• W2894897498 cites W2041673115 @default.
• W2894897498 cites W2042921846 @default.
• W2894897498 cites W2073332501 @default.
• W2894897498 cites W2079961396 @default.
• W2894897498 cites W2081622555 @default.
• W2894897498 cites W2083975005 @default.
• W2894897498 cites W2087645894 @default.
• W2894897498 cites W2093310669 @default.
• W2894897498 cites W2097063773 @default.
• W2894897498 cites W2106838509 @default.
• W2894897498 cites W2121815683 @default.
• W2894897498 cites W2136956402 @default.
• W2894897498 cites W2157636987 @default.
• W2894897498 cites W2162382402 @default.
• W2894897498 cites W2288647707 @default.
• W2894897498 cites W2337228735 @default.
• W2894897498 cites W2521181071 @default.
• W2894897498 cites W2531626219 @default.
• W2894897498 cites W2598055604 @default.
• W2894897498 cites W2766085740 @default.
• W2894897498 cites W3143409077 @default.
• W2894897498 doi "https://doi.org/10.1002/hep4.1254" @default.
• W2894897498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6287477" @default.
• W2894897498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30556044" @default.
• W2894897498 hasPublicationYear "2018" @default.
• W2894897498 type Work @default.
• W2894897498 sameAs 2894897498 @default.
• W2894897498 citedByCount "21" @default.
• W2894897498 countsByYear W28948974982018 @default.
• W2894897498 countsByYear W28948974982019 @default.
• W2894897498 countsByYear W28948974982020 @default.
• W2894897498 countsByYear W28948974982021 @default.
• W2894897498 countsByYear W28948974982022 @default.
• W2894897498 countsByYear W28948974982023 @default.
• W2894897498 crossrefType "journal-article" @default.
• W2894897498 hasAuthorship W2894897498A5005730211 @default.
• W2894897498 hasAuthorship W2894897498A5017596026 @default.
• W2894897498 hasAuthorship W2894897498A5027038914 @default.
• W2894897498 hasAuthorship W2894897498A5035012194 @default.
• W2894897498 hasAuthorship W2894897498A5045504446 @default.
• W2894897498 hasAuthorship W2894897498A5056496986 @default.
• W2894897498 hasAuthorship W2894897498A5061607493 @default.
• W2894897498 hasAuthorship W2894897498A5075606570 @default.
• W2894897498 hasAuthorship W2894897498A5078994052 @default.
• W2894897498 hasAuthorship W2894897498A5090710640 @default.
• W2894897498 hasBestOaLocation W28948974981 @default.
• W2894897498 hasConcept C126322002 @default.
• W2894897498 hasConcept C141071460 @default.
• W2894897498 hasConcept C156957248 @default.
• W2894897498 hasConcept C188816634 @default.
• W2894897498 hasConcept C2777214474 @default.
• W2894897498 hasConcept C2779102576 @default.
• W2894897498 hasConcept C2780559512 @default.
• W2894897498 hasConcept C2780826214 @default.
• W2894897498 hasConcept C2994217296 @default.
• W2894897498 hasConcept C71924100 @default.
• W2894897498 hasConcept C89560881 @default.
• W2894897498 hasConcept C90924648 @default.
• W2894897498 hasConceptScore W2894897498C126322002 @default.
• W2894897498 hasConceptScore W2894897498C141071460 @default.
• W2894897498 hasConceptScore W2894897498C156957248 @default.
• W2894897498 hasConceptScore W2894897498C188816634 @default.
• W2894897498 hasConceptScore W2894897498C2777214474 @default.
• W2894897498 hasConceptScore W2894897498C2779102576 @default.
• W2894897498 hasConceptScore W2894897498C2780559512 @default.
• W2894897498 hasConceptScore W2894897498C2780826214 @default.
• W2894897498 hasConceptScore W2894897498C2994217296 @default.
• W2894897498 hasConceptScore W2894897498C71924100 @default.
• W2894897498 hasConceptScore W2894897498C89560881 @default.
• W2894897498 hasConceptScore W2894897498C90924648 @default.
• W2894897498 hasIssue "12" @default.
• W2894897498 hasLocation W28948974981 @default.
• W2894897498 hasLocation W28948974982 @default.
• W2894897498 hasLocation W28948974983 @default.

• next